Autologous cell therapies: challenges in US FDA regulation.
about
Tissue engineering and regenerative medicine: semantic considerations for an evolving paradigm.Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications.Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.Disruptive technological advances in vascular access for dialysis: an overview.
P2860
Autologous cell therapies: challenges in US FDA regulation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Autologous cell therapies: challenges in US FDA regulation.
@en
Autologous cell therapies: challenges in US FDA regulation.
@nl
type
label
Autologous cell therapies: challenges in US FDA regulation.
@en
Autologous cell therapies: challenges in US FDA regulation.
@nl
prefLabel
Autologous cell therapies: challenges in US FDA regulation.
@en
Autologous cell therapies: challenges in US FDA regulation.
@nl
P2093
P2860
P356
P1476
Autologous cell therapies: challenges in US FDA regulation.
@en
P2093
David Audley
Nicolas L'Heureux
Todd N McAllister
P2860
P356
10.2217/RME.12.83
P433
P577
2012-11-01T00:00:00Z